These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 16740759)

  • 1. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
    Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
    Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R; Oberthuer A; Zapatka M; Brors B; Hero B; Ernestus K; Oestreich J; Fischer M; Simon T; Berthold F
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
    Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
    Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
    Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
    Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
    J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity for chromosome 14q in neuroblastoma.
    Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
    Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
    Gehring M; Berthold F; Edler L; Schwab M; Amler LC
    Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
    Maris JM; Guo C; Blake D; White PS; Hogarty MD; Thompson PM; Rajalingam V; Gerbing R; Stram DO; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):32-6. PubMed ID: 11464900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.